Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

NCT04323748 ·Status: RECRUITING ·Phase: PHASE1

A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00504075 ·Status: COMPLETED ·Phase: PHASE3

Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP

NCT05613296 ·Status: COMPLETED

Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study

NCT06071520 ·Status: COMPLETED

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

NCT07194850 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP

NCT00571467 ·Status: TERMINATED ·Phase: PHASE1

Special Drug Use-results Survey for Long-term Use (Fostamatinib)

NCT06757257 ·Status: RECRUITING

A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

NCT06831058 ·Status: RECRUITING ·Phase: PHASE2

Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura

NCT05093257 ·Status: UNKNOWN

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

NCT01713855 ·Status: COMPLETED ·Phase: NA

An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP

NCT00508820 ·Status: COMPLETED ·Phase: PHASE3

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT01713738 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

NCT01101295 ·Status: UNKNOWN

Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

NCT00168038 ·Status: COMPLETED ·Phase: PHASE3

Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

NCT00116688 ·Status: COMPLETED ·Phase: PHASE3

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

NCT04543279 ·Status: TERMINATED ·Phase: PHASE2

Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)

NCT00372892 ·Status: COMPLETED ·Phase: PHASE2

IGIV Study for Chronic ITP Patients Ages 3-70

NCT00511147 ·Status: COMPLETED ·Phase: PHASE3

Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

NCT00005652 ·Status: COMPLETED ·Phase: PHASE2

Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP

NCT07057778 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

NCT00770562 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

NCT05070845 ·Status: RECRUITING ·Phase: PHASE2

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

NCT01143038 ·Status: COMPLETED ·Phase: PHASE2

A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

NCT00161564 ·Status: WITHDRAWN ·Phase: PHASE2

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT05468320 ·Status: COMPLETED ·Phase: PHASE3